Published in Transl Oncol on June 01, 2010
The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer (2013) 4.20
ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. Clin Cancer Res (2015) 1.50
Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J Carcinog (2011) 1.13
TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. J Cancer Sci Ther (2012) 0.97
Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer. Am J Transl Res (2013) 0.96
The oncogene ERG: a key factor in prostate cancer. Oncogene (2015) 0.93
Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Hum Mutat (2013) 0.92
Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions. Mol Cancer Res (2013) 0.89
Targeting bone physiology for the treatment of metastatic prostate cancer. Clin Adv Hematol Oncol (2013) 0.80
CXCR4 is a novel target of cancer chemopreventative isothiocyanates in prostate cancer cells. Cancer Prev Res (Phila) (2015) 0.78
BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. Oncotarget (2016) 0.77
Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility. BMC Cancer (2015) 0.77
The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy. Cancer Biol Ther (2014) 0.77
Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells. Cancer Cell Int (2014) 0.76
Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide. Mol Ther Nucleic Acids (2016) 0.75
Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis. Mol Cancer (2016) 0.75
Significantly higher expression levels of androgen receptor are associated with erythroblastosis virus E26 oncogene related gene positive prostate cancer. Am J Clin Exp Urol (2014) 0.75
Considering race and the potential for ERG expression as a biomarker for prostate cancer. Per Med (2014) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol (2004) 6.99
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 5.79
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res (2006) 4.50
The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol (2004) 4.09
NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem (2003) 3.98
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res (2008) 3.39
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol (2008) 2.66
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer (2007) 2.62
Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res (2007) 2.60
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36
Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res (2008) 2.18
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate (2006) 1.86
The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev (2006) 1.69
Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci (2008) 1.67
HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. Carcinogenesis (2006) 1.40
Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res (2008) 1.35
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res (2008) 1.23
Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Commun (2004) 1.14
Two androgen response elements in the androgen receptor coding region are required for cell-specific up-regulation of receptor messenger RNA. Mol Endocrinol (1996) 1.08
Human ERG-2 protein is a phosphorylated DNA-binding protein--a distinct member of the ets family. Oncogene (1993) 1.04
Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep (2006) 0.89
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res (2008) 7.53
Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. BJU Int (2011) 2.12
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate (2006) 1.86
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells (2008) 1.78
Metastasis and AKT activation. Cell Cycle (2008) 1.68
Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem (2007) 1.60
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology (2013) 1.52
Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst (2002) 1.45
Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth. Int J Cancer (2014) 1.39
Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene (2002) 1.38
Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res (2007) 1.37
A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res (2004) 1.36
Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci U S A (2003) 1.34
Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One (2012) 1.33
Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin Cancer Biol (2004) 1.33
Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol (2005) 1.32
Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer (2006) 1.32
Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin. Cancer Res (2006) 1.28
Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci (2005) 1.24
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res (2008) 1.23
Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res (2004) 1.23
p37 Induces tumor invasiveness. Mol Cancer Ther (2005) 1.21
Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J Biol Chem (2005) 1.16
Tumor suppressive maspin and epithelial homeostasis. J Cell Biochem (2006) 1.15
PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol Cancer (2013) 1.14
Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem (2006) 1.14
Circulating tumor cells: finding the needle in the haystack. Am J Cancer Res (2011) 1.13
Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia (2005) 1.11
C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia (2008) 1.11
Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res (2010) 1.10
A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer (2005) 1.10
Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol (2007) 1.09
Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res (2006) 1.08
Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia (2004) 1.05
Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer (2005) 1.05
Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer (2007) 1.04
Maspin is up-regulated in premalignant prostate epithelia. Prostate (2002) 1.04
Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis (2003) 1.03
Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol (2008) 1.03
Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer (2003) 1.00
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia (2008) 0.97
Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology (2002) 0.97
TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. J Cancer Sci Ther (2012) 0.97
Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer (2011) 0.97
A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur J Cancer (2010) 0.96
Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer. Nutr Cancer (2010) 0.96
Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. Int J Cancer (2008) 0.95
Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells. J Cell Physiol (2007) 0.95
Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. Clin Exp Metastasis (2003) 0.95
Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis. Urol Oncol (2007) 0.94
Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene (2005) 0.91
HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells. Mol Cancer Res (2011) 0.90
PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer. Am J Pathol (2011) 0.89
Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions. Mol Cancer Res (2013) 0.89
Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. Histopathology (2009) 0.89
Prostate cancer diagnosis, staging and survival. Cancer Metastasis Rev (2002) 0.89
The natural tumor suppressor protein maspin and potential application in non small cell lung cancer. Curr Pharm Des (2010) 0.88
Identification of an intrinsic determinant critical for maspin subcellular localization and function. PLoS One (2013) 0.86
Structural insights into neutrophilic migration revealed by the crystal structure of the chemokine receptor CXCR2 in complex with the first PDZ domain of NHERF1. PLoS One (2013) 0.85
Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate (2011) 0.85
Tumor suppressor maspin as a rheostat in HDAC regulation to achieve the fine-tuning of epithelial homeostasis. Crit Rev Eukaryot Gene Expr (2012) 0.84
Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. BMC Urol (2014) 0.84
Elevated maspin expression is associated with better overall survival in esophageal squamous cell carcinoma (ESCC). PLoS One (2013) 0.84
Matrix metalloproteinaes and bone metastasis. Cancer Treat Res (2004) 0.84
Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis. Clin Exp Metastasis (2006) 0.84
Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction. Urology (2007) 0.83
Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance. Clin Exp Metastasis (2004) 0.82
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. J Urol (2009) 0.80
The mouse prostate: a basic anatomical and histological guideline. Bosn J Basic Med Sci (2016) 0.80
High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy. Urol Oncol (2005) 0.79
Maspin expression patterns differ in the invasive versus lepidic growth pattern of pulmonary adenocarcinoma. Histopathology (2014) 0.78
Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions. Cancer (2003) 0.77
Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC. Cancer Biol Ther (2006) 0.76
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects). Pathol Oncol Res (1996) 0.76
Presence of circulating prostate cancer cells in African American males adversely affects survival. Urol Oncol (2002) 0.76
Tumor suppressor maspin as a modulator of host immune response to cancer. Bosn J Basic Med Sci (2015) 0.75
Elevated levels of angiostatin in effusions from patients with malignant disease. Oncol Rep (2004) 0.75
Quantitative assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging. Prostate (2007) 0.75